We are live on ! Find out more
SNNA

Sienna Biopharmaceuticals, Inc.
SNNA

Delisted

SNNA was delisted on the 16th of December, 2019.

Back to rankings

4 hedge funds and large institutions have $2.07K invested in Sienna Biopharmaceuticals, Inc. in 2019 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

83% less funds holding

Funds holding: 23 → 4 (-19)

95% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 20

100% less capital invested

Capital invested by funds: $1.08M → $2.07K (-$1.08M)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
4
Holders Change
-19
Holders Change %
-82.61%
% of All Funds
0.08%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
1
Closed
20
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
PO
Private Ocean
California
+$102

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$920K
2
GSWM
Golden State Wealth Management
California
-$36K
3
Millennium Management
Millennium Management
New York
-$24K
4
BlackRock
BlackRock
New York
-$18K
5
Citadel Advisors
Citadel Advisors
Florida
-$17K

SNNA Hedge Fund Activity: Q4 2019 in Review

4 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in Sienna Biopharmaceuticals, Inc. (SNNA) for Q4 2019, worth a combined $2.07K — down 100% from $1.08M a quarter earlier.

Sellers outnumbered buyers: 20 funds closed out of SNNA and 1 opened new positions — a net loss of 19 holders — while 1 trimmed existing stakes and 0 added.

The largest buyer was Private Ocean, opening a new position worth an estimated $102. The largest seller was Fidelity Investments, exiting entirely with an estimated $920K sold.

  • 4 institutional investors held Sienna Biopharmaceuticals, Inc. (SNNA) as of Q4 2019, down from 23 in Q3 2019.
  • Funds reported $2.07K of Sienna Biopharmaceuticals, Inc. stock for Q4 2019, down 100% quarter-over-quarter.
  • 1 fund opened new Sienna Biopharmaceuticals, Inc. positions in Q4 2019 and 20 closed out, a net change of -19 holders.
  • The largest Sienna Biopharmaceuticals, Inc. buyer in Q4 2019 was Private Ocean, an estimated $102 added.
  • The largest Sienna Biopharmaceuticals, Inc. seller in Q4 2019 was Fidelity Investments, an estimated $920K sold.

Based on aggregated 13F filings for Q4 2019.